SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026
MWN-AI** Summary
Sera Prognostics, Inc. (Nasdaq: SERA), known for its innovative work in maternal and neonatal health, has announced a conference call and webcast to discuss its financial results for the fourth quarter and fiscal year ending 2025. The report will be released on March 18, 2026, after the market closes, followed by a live discussion at 5:00 p.m. Eastern Time. A press release with the financial highlights will be made available prior to the call.
The call can be accessed by US callers at (800) 836-8184 or by international callers at (646) 357-8785. Additionally, the live audio can be accessed via the company's Investors webpage. An archive of the webcast will be kept online for a year.
Sera Prognostics focuses on improving pregnancy outcomes through precision medicine. The company is particularly noted for its PreTRM® Test, a blood-based biomarker test designed to provide early and individualized risk assessments for preterm births. The PreTRM® Test enables healthcare providers to identify at-risk pregnancies between weeks 18 to 20, facilitating timely medical interventions to reduce the risk of premature deliveries, which are a leading cause of neonatal health issues.
Preterm birth, categorized as any birth before 37 weeks of gestation, poses significant health risks for newborns and accounts for considerable healthcare costs, estimated at $25 billion for managing complications linked to prematurity in the U.S. alone.
As a publicly traded entity, Sera Prognostics remains committed to its mission while facing potential market uncertainties and risks, which it discusses comprehensively in its regulatory filings. Investors can find more information and updates leading up to the call on the company's official website.
MWN-AI** Analysis
Sera Prognostics, Inc. (NASDAQ: SERA) is poised to report its fourth quarter and fiscal year 2025 financial results on March 18, 2026. For investors, this conference call and webcast offer an important opportunity to gauge the company’s performance and future outlook, particularly in a sector as critical as maternal and neonatal health.
As the leader in pregnancy diagnostics, Sera's PreTRM® Test holds significant potential in a market that grapples with high preterm birth rates. The recent D+ grade from the March of Dimes underscores the pressing need for effective interventions, which positions Sera’s innovative solutions favorably in the healthcare landscape. The early prediction capability of the PreTRM® Test will likely attract increasing attention from both healthcare professionals and potential investors, especially as awareness of preterm birth complications rises.
Investors should closely monitor the financial results for key indicators of market traction, including revenue growth and adoption rates of the PreTRM® Test. It is crucial to assess whether revenues are diversifying beyond the test itself, as the company's dependence on a single product represents a risk factor. Additionally, any updates regarding insurance reimbursement policies and coverage could markedly influence the company’s financial health and market expansion ability.
In advance of the earnings call, it is advisable to analyze trading volumes and market sentiment around SERA shares. A positive reception to the performance results and strategic plans communicated during the call could generate upward momentum in the stock. Conversely, investors should prepare for volatility if the results reveal shortcomings or if management highlights significant risks, such as competitive pressures or regulatory challenges.
Ahead of March 18, consider establishing a watchlist for Sera Prognostics to capture real-time market reactions, allowing for informed investment decisions based on the information unveiled during the earnings call.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Conference Call Details:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/rd0XDOVL85p
Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
SOURCE Sera Prognostics, Inc.
FAQ**
What key financial metrics and operational highlights can we expect Sera Prognostics Inc. SERA to discuss during their conference call on March 18, 2026?
How does Sera Prognostics Inc. SERA plan to address the challenges surrounding reimbursement methodologies for the PreTRM® Test mentioned in their risk factors?
Given the concentrated customer base mentioned, what strategies is Sera Prognostics Inc. SERA implementing to diversify their revenue streams and reduce the associated risks?
What advancements or updates on the PreTRM® Test's market acceptance and competitive landscape will Sera Prognostics Inc. SERA provide during the webcast?
**MWN-AI FAQ is based on asking OpenAI questions about Sera Prognostics Inc. (NASDAQ: SERA).
NASDAQ: SERA
SERA Trading
-4.52% G/L:
$1.90 Last:
638 Volume:
$1.90 Open:
